Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity

Breast Cancer Research and Treatment

Volumn 109, Issue 3, 2008, Pages 443-450

  Sakaguchi, Hiromi ^a   Kodama, Ayumi ^a   Tomonari, Mari ^b   Ando, Yukie ^a   Tabuchi, Mayumi ^a   To, Hideto ^b   Araki, Ryosuke ^b   Kitahara, Takashi ^b   Sasaki, Hitoshi ^b   Ohdo, Shigehiro ^a   Higuchi, Shun ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Adriamycin; Cardiotoxicity; Combination therapy; Docetaxel; Dosing interval

Indexed keywords

CREATINE KINASE ISOENZYME; DOCETAXEL; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG TOLERANCE; ENZYME ACTIVITY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DOXORUBICIN; HEART; MALE; MICE; MICE, INBRED ICR; NEOPLASMS, EXPERIMENTAL; TAXOIDS;

EID: 43749116512     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9667-8     Document Type: Article

References (27)

1. Hortobagyi GN (1998) Treatment of breast cancer. N Eng J Med 339:974-984
2. Stockler M, Wilcken NR, Ghersi D et al (2000) Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 26:151-168
3. Nabholtz JM (1999) Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol 26:7-13
4. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975
5. Mattioli R, Lippe P, Massacesi C et al (2004) Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial. Anticancer Res 24:3257-3262
6. Miller KD, McCaskill-Stevens W, Sisk J et al (1999) Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037
7. Palmeri S, Leonardi V, Tamburo De et al (2002) Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. Oncology 63:205-212
8. Morabito A, Gattuso D, Stani SC et al (2004) Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat 86:249-257
9. To H, Shin M, Tabuchi M et al (2004) Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Clin Cancer Res 10:762-769
10. Tabuchi M, To H, Sakaguchi H et al (2005) Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. Cancer Res 65:8448-8454
11. To H, Ohdo S, Shin M et al (2003) Dosing-time dependency of adriamycin-induced cardiotoxicity and bone marrow toxicity in rats. J Pharm Pharmacol 55:803-810
12. von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717
13. Teraoka K, Hirano M, Yamaguchi K et al (2000) Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2:373-378
14. Thomas L, Bellmont S, Christen MO et al (2004) Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. Fundam Clin Pharmacol 18:649-655
15. Ganem G, Tubiana-Hulin M, Fumoleau P et al (2003) Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:1623-1628
16. Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587-2593
17. Mordente A, Meucci E, Martorana GE et al (2001) Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52:83-88
18. Olson RD, Mushlin PS, Brenner DE et al (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585-3589
19. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076-3086
20. Myers CE, McGuire WP, Liss RH et al (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167
21. Tong J, Ganguly PK, Singal PK (1991) Myocardial adrenergic changes at two stages of heart failure to adriamycin treatment in rats. Am J Physiol 260:909-916
22. Bachur NR, Gordon SL, Gee MV (1977) Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13:901-910
23. Timao Li, Singal PK (2000) Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102:2105-2110
24. al-Harbi MM, al-Gharably NM, al-Shabanah OA et al (1992) Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother Pharmacol 31:200-204
25. Tesoriere L, Ciaccio M, Valenza M et al (1994) Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther 269:430-436
26. Li T, Danelisen I, Singal PK (2002) Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem 232:19-26
27. Siveski-Iliskovic N, Hill M, Chow DA et al (1995) Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91:10-15